Climb Bio (CLYM) Competitors $1.50 +0.06 (+3.82%) As of 02/21/2025 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends CLYM vs. GLUE, AURA, CMRX, UPB, RVNC, ATAI, PHAT, ESPR, TERN, and ACBShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Monte Rosa Therapeutics (GLUE), Aura Biosciences (AURA), Chimerix (CMRX), Upstream Bio (UPB), Revance Therapeutics (RVNC), Atai Life Sciences (ATAI), Phathom Pharmaceuticals (PHAT), Esperion Therapeutics (ESPR), Terns Pharmaceuticals (TERN), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Monte Rosa Therapeutics Aura Biosciences Chimerix Upstream Bio Revance Therapeutics Atai Life Sciences Phathom Pharmaceuticals Esperion Therapeutics Terns Pharmaceuticals Aurora Cannabis Climb Bio (NASDAQ:CLYM) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends. Which has stronger valuation & earnings, CLYM or GLUE? Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$35.12M-$2.13-0.70Monte Rosa TherapeuticsN/AN/A-$135.35M-$1.83-3.40 Which has more volatility and risk, CLYM or GLUE? Climb Bio has a beta of -0.24, suggesting that its share price is 124% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Do institutionals and insiders believe in CLYM or GLUE? 69.8% of Climb Bio shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 3.2% of Climb Bio shares are held by company insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer CLYM or GLUE? Climb Bio presently has a consensus target price of $10.00, indicating a potential upside of 568.90%. Monte Rosa Therapeutics has a consensus target price of $14.00, indicating a potential upside of 125.08%. Given Climb Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Climb Bio is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media prefer CLYM or GLUE? In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Climb Bio. MarketBeat recorded 1 mentions for Monte Rosa Therapeutics and 0 mentions for Climb Bio. Monte Rosa Therapeutics' average media sentiment score of 1.90 beat Climb Bio's score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Climb Bio Neutral Monte Rosa Therapeutics Very Positive Is CLYM or GLUE more profitable? Climb Bio's return on equity of -42.21% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -42.21% -41.39% Monte Rosa Therapeutics N/A -62.68%-38.83% Does the MarketBeat Community believe in CLYM or GLUE? Monte Rosa Therapeutics received 12 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 46.67% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformClimb BioOutperform Votes2100.00% Underperform VotesNo VotesMonte Rosa TherapeuticsOutperform Votes1446.67% Underperform Votes1653.33% SummaryMonte Rosa Therapeutics beats Climb Bio on 9 of the 16 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.80M$7.06B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.705.7326.0419.11Price / SalesN/A306.03447.4676.36Price / CashN/A65.6738.0134.83Price / Book0.386.717.644.62Net Income-$35.12M$138.33M$3.18B$245.85M7 Day Performance-1.64%-2.63%-2.00%-2.61%1 Month Performance-20.05%-2.33%-0.44%-2.14%1 Year PerformanceN/A-5.33%16.44%12.98% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio2.4945 of 5 stars$1.50+3.8%$10.00+568.9%N/A$96.80MN/A-0.709GLUEMonte Rosa Therapeutics2.6664 of 5 stars$6.25+2.2%$14.00+124.1%+13.1%$398.01MN/A-3.5490Positive NewsAURAAura Biosciences3.2166 of 5 stars$7.91+2.3%$23.00+190.9%-14.7%$395.41MN/A-4.5850CMRXChimerix4.3492 of 5 stars$4.35-2.1%$8.50+95.6%+333.9%$394.84M$320,000.00-4.6790Analyst ForecastAnalyst RevisionNews CoverageUPBUpstream BioN/A$7.34+3.5%$56.50+670.1%N/A$393.42MN/A0.0038Upcoming EarningsRVNCRevance Therapeutics4.2006 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Upcoming EarningsAnalyst ForecastATAIAtai Life Sciences3.114 of 5 stars$2.23-12.5%$9.00+303.2%+5.9%$375.54M$310,000.00-2.7680Insider TradeNews CoveragePHATPhathom Pharmaceuticals2.5212 of 5 stars$5.46+1.3%$23.00+321.2%-44.5%$372.67M$680,000.00-0.96110ESPREsperion Therapeutics4.4488 of 5 stars$1.87-0.8%$6.75+261.9%-30.1%$369.45M$116.33M-2.93200Gap DownTERNTerns Pharmaceuticals4.4051 of 5 stars$4.26-1.0%$18.30+330.1%-50.4%$369.06MN/A-3.6840ACBAurora Cannabis0.5205 of 5 stars$6.70+5.9%N/A+73.2%$365.64M$200.35M133.331,073 Related Companies and Tools Related Companies Monte Rosa Therapeutics Competitors Aura Biosciences Competitors Chimerix Competitors Upstream Bio Competitors Revance Therapeutics Competitors Atai Life Sciences Competitors Phathom Pharmaceuticals Competitors Esperion Therapeutics Competitors Terns Pharmaceuticals Competitors Aurora Cannabis Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLYM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLYM Stock Alerts